Background/Aims: Vascular endothelial growth factor (VEGF) is an endothelium-specific peptide that stimulates angiogenesis via two receptor tyrosine kinases, Flt-1 and KDR.
Introduction
Vascular endothelial growth factor (VEGF) is an endothelium-specific peptide that potently stimulates angiogenesis, vasodilation, and microvascular hyperpermeability. Hypoxia upregulates VEGF production and release in a wide variety of cells and organs [1] . The angiogenic effects of VEGF are mediated through binding to its specific tyrosine kinase receptors: VEGFF-R1 (fms related tyrosine kinase 1; FLT-1) and VEGF-R2 (Kinase insert domain receptor; KDR). The Flt-1 receptor has a higher affinity for VEGF, yet its role in the vasculature is poorly understood [2] . Gille et al have demonstrated that KDR mediates many of the known activities of VEGF in endothelial cells, including chemotaxis, survival, mitogenesis, and vascular permeability [3] .
Recent reports indicate that nitric oxide (NO) may play a crucial role in VEGF signaling [4] . Hood et al have shown that, in endothelial cells, VEGF elicits a dose-dependent increase in cellular content of endothelial cell nitric oxide synthase (eNOS) message and protein which was associated with augmented NO generation [5] . Bouloumie et al have demonstrated that VEGF induces an increase in both eNOS mRNA and protein levels and increases basal NO generation, as indicated by the elevation of cGMP levels in cultured endothelial cells, and enhanced endothelium-mediated relaxation of aortic rings [6, 7] . We focus our interest on the role of intra-cellular arginine availability in governing eNOS activity, thus affecting endothelial function. We have previously hypothesized that delivery of transported arginine to membrane-bound eNOS, selectively by the cationic amino acid transporter-1 (CAT-1), rather than intra or extra-cellular arginine concentrations, is a predominant factor governing eNOS activity. Indeed, we have shown in several different animal models that eNOS and CAT-1 activity behave in a similar manner [8] [9] [10] [11] [12] [13] .
The experiments reported herein were designed to test the hypothesis that VEGF enhances eNOS activity via modulation of arginine uptake. We have selectively silenced the expression of either Flt-1 or KDR receptor in primary cultures of human umbilical vein endothel cells (HUVECs) and evaluated the contribution of each individual receptor in mediating VEGF effect on cellular L-arginine transport.
Materials and Methods

Cells, hormones and chemicals
Fresh unpassaged HUVEC were obtained from Promo Cell GmbH, Heidelberg, Germany. Upon arrival, the cells were cultured according to the manufacturer's instructions as previously described [15] . Cells were used for experiments when they were 70-80% confluent, between passages 3 and 6. Twenty four hours prior to all experiments, the incubation medium was changed to 5% bovine serum albumin (BSA). All reagents were purchased from Sigma-Aldrich, unless indicated otherwise.
L -Arginine Uptake in HUVEC
Uptake of radiolabeled L-arginine in HUVEC was measured according to previously described methods [14] . In brief, cells were seeded onto 6-well plates (Corning) at a density of 10 6 cells/well. When confluent, cells were washed with 1 ml HEPES buffer, pH 7.4 at 37 °C. L-[H 3 arginine] and L-arginine, in a final concentration of 100µM, were added to a total volume of 1 ml for 1 min. Transport was terminated by rapidly washing the cells with ice-cold PBS buffer (4 times, 1 ml/well). The cells were then dried and solubilized in 1 ml of 0.5% SDS in 0.5 N NaOH. To monitor radioactivity by liquid scintillation spectrometry (Betamatic; Kontron), 700 μl of the lysate was used. The remaining 300 μl was used for protein content determination by the Lowry method (Lowry Assay Kit; Sigma Co.). Results are expressed as mean ± SE of at least five different experiments.
Nitrite/nitrate determination
The level of nitrite/nitrate concentrations in the conditioned medium was measured using a nitric oxide detection kit (ENZO Life Sciences) according to the manufacturer's instructions as previously described [15] . In brief, following filtration in a 10 Kd spin column (Biovision INC. CA, USA) 50 µl of the culture medium was diluted with 50 µl of reactive buffer containing 50 µM L-N6-(1-iminoethyl) lysine hydrochloride (L-NIL, a selective inducible NOS inhibitor), and mixed with 25 µl NADH and 25 µl nitrate reductase. Following incubation to convert nitrate to nitrite Griess reagents were added, which reacted with nitrite to yield a diazochromophore. Total nitrite was measured at 540 nm. Results of at least six experiments were used for statistical analysis.
SiRNA transfection
Chemically synthesized Flt-1 siRNA, KDR SiRNA and negative control SiRNA were used for transfection (Dharmacon ON-TARGET plus SMART pool and ON-TARGET plus non targeting pool). In brief, 0.5*10 5 cells/well were grown in 6 well plates overnight to 70-80% confluence. Each of the above SiRNA was transfected into cells using lipofectamine 2000 transfection reagent (Invitrgen) according to the manufacturer's instructions. Following SiRNA transfection, cells were lysed and extracted protein was used for Western blotting.
Protein Quantification by Western Blotting
Endothelial CAT-1, PKC-α, phosphorylated PKC-α (p-PKC-α), MAPK extracellular-signal regulated kinase (ERK), phosphorylated ERK (p-ERK), MAPK Jun N-terminal kinase (JNK) and phosphorylated JNK (p-JNK) protein expression were determined by immunoblotting as previously described [16] . In brief, cells were separately placed in ice-cold PBS lysis buffer (pH 7.4), containing protease inhibitors, then mechanically homogenized and left on ice for 45 min. Homogenates were subsequently centrifuged and cell lysates were stored in aliquots at -80 °C. A membrane fraction was obtained by adding to the pellet an equal volume of lysis buffer supplemented by Tween-20 (0.25%) to solubilize. The protein content of each sample was determined by the method of Lowry. Membranes were then incubated with rabbit anti-human CAT-1, ERK, p-ERK, p-PKC-α and mouse monoclonal anti PKC-α, JNK, p-JNK antibodies, rabbit monoclonal anti Flt-1 1:5000 and rabbit polyclonal anti KDR 1:500 (Santa Cruz Biotechnology, Inc., CA, USA) for 1 h at room temperature, washed, and incubated with secondary HRP-conjugated goat anti rabbit and goat anti mouse antibodies in PBS-T for 1 hr. Membranes were then stripped and reprobed with monoclonal anti-β-actin or Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies as an internal control. The reactive bands corresponding to CAT-1, ERK, p-ERK, p-PKC-α, PKC-α, JNK and p-JNK were detected by enhanced chemiluminescence (Kodak X-Omat AR film) and quantified by densitometry.
Statistical Analysis
Values shown in the figures are mean ± SE from data obtained from 5-8 experiments. ANOVA test was applied for comparisons of mean, and then Bonferroni's test was performed. p values< 0.05 were considered to be statistically significant.
Results
Based on our previous reports, the kinetic properties of endothelial arginine transport system resemble those of CAT-1 [15] .
Our first set of experiments was designed to explore the effects of VEGF on CAT-1-related arginine transport. Incubating cells with VEGF (50 and 100 ng/ml) significantly augmented arginine transport in a time dependent manner (Fig. 1a) . The increase in VEGF (50 ng/ml) induced arginine transport was completely prevented by Sunitinib (2 µM), a multi targeted receptor tyrosine kinase inhibitor (Fig. 1b) .
Using Western blot analysis, transfection of either Flt-1 or KDR siRNA resulted in a profound reduction of each receptor protein level respectively compared to scrambeled siRNA transfected cells (Fig. 2a,b) . Experiments were conducted to investigate the specific role of each VEGF receptor on arginine transport. The increase in arginine transport velocities by VEGF was not affected by Silencing Flt-1 (Fig. 2c) , while silencing KDR abrogated VEGF effect on arginine transport (Fig. 2d) .
In addition, placenta growth factor-1 (PGF-1), a selective Flt-1 agonist had no effect on arginine transport (Fig. 2e) . To investigate whether VEGF effect on arginine transport is mediated through CAT-1, CAT-1 protein levels were studied. We have found that incubating cells with 50 and 100 ng of VEGF for 30 minutes significantly augmented CAT-1 abundance (Fig. 3) .
Our next set of studies was performed to identify a specific signal transduction pathway by which VEGF affects arginine uptake. We chose to examine PKC-α, JNK, and ERK1/2, which have been previously shown to modulate eNOS or CAT-1 signaling pathways [16] Utilizing Western blotting we found that the expression of PKC-α, JNK, and ERK1/2 and their phosphorylated forms were unchanged following incubation of HUVEC with VEGF 100 ng/ml for 60 (data not shown).
Finally, Nitrite/nitrate generation by cells exposed to VEGF (50 and 100 ng/ml for 60 minutes) in the presence of L-NIL ( a selective iNOS inhibitor), with or without L-NAME (a non selective NOS inhibitor) was measured in order to evaluate NO production by eNOS. Indeed, the concentration of NO2/NO3 following incubation with VEGF was significantly higher than from untreated cells (Fig. 4a) . The increase in NO generation by VEGF in Flt-1siRNA treated cells was significantly lower relative to control siRNA treated cells. In contrast KDR silencing almost completely abrogated VEGF effect (Fig. 4b,c) .
Discussion
The present study demonstrates, for the first time to our knowledge, that VEGF augments NO generation in HUVEC through modulation of arginine transport.
VEGF regulates angiogenesis, at least partly via NO generation [4] . It binds and activates two tyrosine kinase receptors VEGFR1 (Flt-1) and VEGFR2 (KDR) but the role of each receptor in NO generation has not been fully defined. Bussolati VEGF was completely abolished by anti Flt-1 antibodies whereas the anti KDR antibody had no effect [17] . Nakagawa et al have shown that VEG-induced NO stimulation via Flt-1 is essential to prevent endothelial cell proliferation and migration [18] . In contrast, Shen porcine aortic endothelial cell line through activation of a down stream PKC signaling pathway [19] .
In the current experiments we have tried to resolve the aforementioned controversy by implementing a different approach. We looked at the effect of selective VEGF receptor stimulation on arginine uptake by CAT-1, a major NO synthesis regulator. We found that silencing the KDR receptor almost completely prevented the increase in arginine uptake by VEGF while silencing Flt-1 had a negligible effect on this system. Furthermore, treating cells with PGF-1, a selective Flt-1 agonist had no effect on arginine transport. These data suggest that stimulation of endothelial derived NO synthesis by VEGF occurs predominantly via KDR activation.
B A C
Indeed, Flt-1 has been suggested to act as a negative modulator of angiogenesis. More specific, a strong correlation between plasma levels of soluble form of Flt-1 and preeclampsia has been reported in several studies in both pregnant animals and women [20, 21] . More recently, Burke et al have demonstrated that soluble Flt-1 promotes vasoconstriction which is characteristic of preeclampsia by increasing angiotensin II sensitivity [22] . The current experiments explore a novel mechanism which may explain the anti angiogenic properties of sFlt-1, namely, a failure to stimulate arginine transport and hence NO generation. In the aggregate, it appears that VEGF promotes endothelial NO generation through several mechanisms of which one or more predominate in a specific situation. We have previously shown that during pregnancy, maternal arginine transport is significantly decreased [9] . One can hypothesize that the mechanism suggested herein, namely, induction of arginine transport by CAT-1 dominates in situations characterized by arginine depletion such as pregnancy while in diabetes where arginine transport increases [13] , other pathways prevail. Alternatively, this heterogeneity can be attributed to utilization of different cell lines. Future experiments are needed to determine whether, the decrease in maternal arginine transport contributes to the pathogenesis of preeclampsia, which is characterized by elevated soluble Flt-1 level.
We have tried to elucidate a molecular mechanism to explain our findings. Changes in arginine uptake due to VEGF were associated with directional changes in the amount of CAT-1 protein. We have previously reported, in four different experimental models characterized by diminished arginine transport, namely hypercholesterolemia, chronic renal failure, pregnancy, and aging in the male rat, a post-translational modulation of CAT-1 which was associated with upregulation of PKC-α [8, 11, 12] . In addition, both MAPK's JNK and ERK1/2 were found to modulate CAT-1 [16] . Therefore, we pursued with experiments looking at these proteins as a possible link between VEGF and CAT-1. However, using Western blotting, neither of these signal transduction pathways nor their phosphorylated forms were affected by VEGF. This finding is in contrast with a previous study which showed that VEGF induces endothelial cell proliferation through the KDR ERK 1/2 pathway [18] , and therefore, the pathway by which VEGF activates CAT-1 remains elusive.
Conclusion
VEGF increases arginine transport via modulation of CAT-1 in endothelial cells and this effect is exclusively mediated by KDR but not Flt-1.
